Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
Authors' conclusion
Empagliflozin provides an early reduction of CAT; however, no association was observed with concurrent changes in cardiac volumetrics.
Study context
- Population
- Patients with T2D and established or high risk of CVD78 analysed
- Participants
- 90 patients
- Comparison
- Empagliflozin 25 mg vs placebo for 13 weeks
- Primary endpoint
- Change in cardiac adipose tissue volume (CAT) by 82Rb-PET/CT
- Follow-up
- 13 weeks
Methodological detailssubstudy, placebo-controlled, Randomized 4 April 2017 to 11 May 2020
- Substudy
- Placebo-controlled
- Randomized 4 April 2017 to 11 May 2020
Primary result
Change in CAT
Difference
12.41 ml
95% CI −23.83 to −0.99
P = 0.034
As reported in the abstract
Further findings
| Outcome | Difference (g) (95% CI) | P value | |
|---|---|---|---|
| Left ventricular mass · 13 weeks | −5.16 (−8.80 to −1.52) | P = 0.006 | |
| −10−505Difference, g (linear scale) |
End-diastolic and end-systolic volume · 13 weeks
- End-diastolic volume and end-systolic volume decreased with empagliflozin
Body composition and glucose and lipid metabolism
- Significant improvements in body composition, with reduced total fat mass, and in glucose and lipid metabolism measures
Association of CAT change with cardiac parameters
- No correlation between changes in CAT and in cardiac parameters; CAT change appeared mediated primarily by weight change
Original publication
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial. Diabetes Obes Metab. Published 3 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →